drugset / Trial / NCT05148377
UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this study was to verify the clinical non-inferiority of the pharmacodynamic effects and the safety of use of the drug Heptar® manufactured by Eurofarma Laboratory, compared to the drug Liquemine®, manufactured by by Roche Laboratory in patients with renal failure undergoing hemodialysis treatment
Timeline
- Start
- 2007-08-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Heparin | Other / unclassified | 150 iu/kg | Other |
| Subject | Heptar | Unknown | 150 iu/kg | Other |
Indications
No indication recorded.